| Dec'17 | Dec'16 | |||||
|---|---|---|---|---|---|---|
ASSETS | ||||||
Non-current assets | ||||||
Intangible assets | ||||||
6,195 | 6,195 | |||||
Other non-current assets | ||||||
23 | - | |||||
Total non-current assets | ||||||
6,218 | 6,195 | |||||
Current assets | ||||||
Prepaid expenses and other receivables | ||||||
317 | 401 | |||||
Cash | ||||||
22,651 | 21,829 | |||||
Total current assets | ||||||
22,969 | 22,230 | |||||
Total assets | ||||||
29,187 | 28,426 | |||||
LIABILITIES | ||||||
Non-current liabilities | ||||||
Term loan, net of deferred financing costs | ||||||
14,057 | - | |||||
Other non-current liabilities | ||||||
22 | - | |||||
Total non-current liabilities | ||||||
14,079 | - | |||||
Current liabilities | ||||||
Trade and other payables | ||||||
10,889 | 12,319 | |||||
Payable on completion of clinical trial | ||||||
500 | 500 | |||||
Derivative liabilities | ||||||
12,626 | 5,798 | |||||
Total current liabilities | ||||||
24,015 | 18,617 | |||||
Total liabilities | ||||||
38,095 | 18,617 | |||||
Net (liabilities) assets | ||||||
-8,907 | 9,809 | |||||
EQUITY | ||||||
Share capital | ||||||
3,589 | 2,728 | |||||
Share premium | ||||||
80,872 | 57,348 | |||||
Group reorganization reserve | ||||||
9,938 | 9,938 | |||||
Accumulated deficit | ||||||
-103,308 | -60,205 | |||||
Total (deficit) equity | ||||||
-8,907 | 9,809 | |||||